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Background: Evolving standards of good publication practice (GPP) and a survey conducted in 2009 of authors,
who were investigators and researchers not employed by the company prompted changes to GSK Vaccines’
publication practices. We conducted a follow-up survey in 2012 to assess the company’s revised practices and to
evaluate understanding of GPP among investigators and researchers who had previously authored at least one
publication in collaboration with GSK Vaccines.
Methods: The 50-question web-based survey addressed authoring practices and transparency of decision-making.
Investigators and researchers (n = 1,273) who had authored at least one publication reporting on GSK
Vaccines-sponsored human research since 2007, were invited to participate. Responses to 37 closed questions are
presented. The remaining 13 questions were open-ended or did not concern publication practices.
Results: A total of 415 external authors (32.6%) responded. International Committee of Medical Journal Editors
(ICMJE) authorship criteria were clear to most respondents (78.1%); 7.7% found they were unclear. The majority of
participants (86.8%) found GSK Vaccines’ authorship questionnaire a suitable tool to assess eligibility for authorship
as per the ICMJE criteria. However, only 68.5% felt that the outcome of the questionnaire is communicated
appropriately and 58.3% felt well informed on changes in authorship. Nearly two-thirds (62.9%) of respondents
felt that having a pharmaceutical company employee as lead author makes manuscript acceptance less likely. Access
to relevant data was regarded as sufficient by 78.5% of respondents. Briefing meetings before publication start,
publication steering committees and core writing teams were recognized as valuable publication practices.
Professional medical writing support was seen as adding value to publication development by 87.7% of participants.
Most respondents agreed that manuscript discussions should start early, with 81.7% stating that they were in favor of
introducing a formalized ‘author agreement’ at the publication start.
Conclusions: GSK Vaccines made changes to its publication practices to ensure improved transparency and better
involvement of external authors. The results of this survey suggest that these changes have been effective to a large
extent. They confirm the need for effective and timely communication, as well as transparent processes for
authorship and decision-making during publication development. The identified gaps in GPP will help to
guide further improvements to the company’s policies on publication practices.
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Authors, researchers and organizations that fund research
share responsibility for developing articles in a trustworthy
and ethical manner [1]. However, practices in the publica-
tion of research study results have been questioned in
relation to issues such as reporting bias, inappropriate
authorship and inaccurate disclosure of conflicts of inter-
est [2-9], not only for industry-sponsored studies, but also
for publicly-funded or academic trials [10-12]. This can
lead to a loss of confidence in the evidence base used to
inform public health decisions [13-15].
Various guidelines have been developed to standardize
the reporting of research and to make an effort to en-
sure ethical standards are maintained in the disclos-
ure of study findings. These include recommendations
from the International Committee of Medical Journal
Editors (ICMJE) for the conduct, reporting, editing and
publication of scholarly work in medical journals [16]. The
good publication practice (GPP) guidelines, which were
published in 2003 [17] and revised by the International
Society for Medical Publication Professionals (GPP2;
GPP3 guidelines are in development), focus on industry-
sponsored research [1]. There are also guidelines for
reporting specific study types, such as the Consolidated
Standards of Reporting Trials (CONSORT) for reporting
randomized trials, the Strengthening the Reporting of
Observational studies in Epidemiology (STROBE) guide-
lines, the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines and the Consoli-
dated Health Economic Evaluation Reporting Standards
(CHEERS) guidelines for economic evaluations of health
interventions [18].
Although many pharmaceutical companies have incor-
porated internationally-recognized best practices in their
publication policies, a persistent negative view of industry-
sponsored studies remains [19,20]. Efforts have therefore
been made by the industry to improve publishing prac-
tices further [10,21-24]. In 2009, GSK Vaccines (a division
of the GlaxoSmithKline group of companies) conducted a
web-based survey to obtain feedback on its publication
practices from 265 external authors (investigators and re-
searchers not employed by the GlaxoSmithKline group of
companies) who had collaborated with the company on at
least one publication. Based on the survey’s findings and
evolving international recommendations for best publi-
cation practices, GSK Vaccines introduced a number
of initiatives to improve transparency and ensure better
involvement of external authors in the decision-making
processes for manuscript development from an early stage
[23]. Measures were also put in place to increase under-
standing of publication standards, including open discus-
sions of responsibilities, authorship and journal selection,
and the introduction of an authorship questionnaire to
determine compliance with ICMJE criteria (see Additionalfile 1) [25]. Company policy on public disclosure of clinical
research includes a ban on ‘ghostwriting’ of journal manu-
scripts and abstracts, with a requirement that any medical
writers who are employees or directly contracted to the
company are either named as authors when eligible, or in-
cluded in the acknowledgements section of manuscripts
[23]. The primary author for a paper must actively partici-
pate in the drafting process, lead content development and
work closely with co-authors in agreeing the final version.
A publications coordinator provides logistical and edi-
torial support to facilitate communication among au-
thors and improve the quality of study reporting with
good publication practice guidance. Publication steering
committees (PSCs) and core writing teams may also be
formed. A web-based file-sharing system (Datavision™;
Envision Technology Solutions, Glastonbury, United
Kingdom) permits centralized documentation and im-
proves transparency in publication practices among users.
In 2012, GSK Vaccines invited nearly 1,300 external
authors working with the company worldwide to partici-
pate in a second web-based survey. As follow-up to the
2009 survey, this had the objective of evaluating feedback
on the usefulness of practices employed to coordinate and
facilitate the development of publications. Another object-
ive was to gain insight into authors’ understanding of key
concepts in publication development relating to author-
ship, opinions on the transparency of publication practices
and decision-making, as well as general perceptions of the
publication of industry-sponsored research.
Methods
The survey questionnaire
The web-based survey was developed and managed by
Deloitte’s health economics department (Brussels, Belgium)
on behalf of GSK Vaccines. The initial proposal document
for conduct of the study can be provided upon request. No
incentive was offered to potential participants to take part
in the survey. The survey questionnaire was first piloted
within GSK Vaccines. The final version of the question-
naire was developed by Deloitte based on feedback
received from participants of the test survey.
The survey included 50 questions in English that did
not require more than 15 minutes to complete and
focused on the main changes that had been implemented
in the company’s publication practices over the previous
two years (survey questionnaire is provided in Additional
file 2). An explanation of terms used in the survey is pro-
vided in Table 1. The survey included six profile questions
relating to the respondent’s institution location, main
research area and number of publications developed in
collaboration with GSK Vaccines and independently. Of
the 44 questions relating to publication practices, 37
had a closed format, and responders indicated the extent
of their agreement with a series of statements (for example,
Table 1 Terminology used in the survey
Term Explanation
Authorship questionnairea [25] Questionnaire for identification of potential authors based on their level of contribution to a study and evaluation
of their interest in authoring, taking public responsibility and critically reviewing and approving the final
version, based on ICMJE criteria. Completed questionnaires are collected at the end of the active phase
of the study, before study results are available.
Publication briefing meeting First meeting with authors and technical support staff (as a minimum: the lead author, the corresponding author,
publication writer and publications coordinator). Purpose is to provide the opportunity for authors to agree on
the publication’s content (interpretation and presentation of results, references), authorship order, target journal,
timelines and working practices.
Publication outline Skeletal presentation of the text that is circulated to all authors as a basis for discussions of the structure and
content of the publication.
Publication steering
committee (PSC) [1]
Small working group of individuals that may include members of the study steering committee and protocol
development team, investigators and other individuals with expertise in the area and scientists of the sponsor
company. Its aim is to endorse and recommend publication activities on behalf of the research study group.
PSC membership does not automatically confer authorship.
Core writing team Subgroup of authors who commit to taking the lead in the development of a publication. All authors review
and provide input to the scientific content of the manuscript.
aSee Additional file 1.
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‘disagree’ or ‘strongly disagree’) or a single response from
a multiple-choice list. Several closed questions incorpo-
rated open follow-up questions to obtain further informa-
tion on specific multiple-choice responses, such as ‘not
clear at all’ or ‘other’. The remaining seven open-ended
questions aimed to obtain opinions on topics such as ways
to improve specific publication practices; responses to
these questions are beyond the scope of this report be-
cause of their qualitative and heterogeneous nature. Four
questions that aimed to obtain further information on
user satisfaction with Datavision and, in order to focus
solely on publication practices, six questions on congress-
related activities were not included.
Survey participants and conduct
All investigators and researchers who had authored at
least one publication reporting GSK Vaccines-sponsored
human subject research since 2007 were invited to
participate. Around 1,300 external authors had worked
with the company during this period and the aim was to
achieve a minimum response rate of 15%.
An email was issued by GSK Vaccines to introduce
Deloitte as project partner and to guarantee confidenti-
ality of feedback. The survey was issued on 22 May 2012
by email, along with a cover letter that explained its pur-
pose, the nature of the group receiving the survey, its ap-
proximate duration and contact details in case of questions
or concerns. Participants were invited to complete the sur-
vey by clicking on a hyperlink in the email that directed
them to the web-based survey. The survey was hosted on a
dedicated website that allowed responses to feed directly
into a survey software tool (SurveyMonkey™ Palo Alto,
CA, USA); Data were kept confidential and stored in a
global database; personal identifying information (includingrespondents’ email addresses) was excluded from survey
and data analysis procedures.
Participants were asked to complete the survey within
three weeks. After two weeks, a reminder was sent to those
who had not completed the survey. A second reminder
was planned to be sent out after four weeks to invite
non-respondents to participate over an extra period of two
weeks. However, as the response rate achieved at the
end of four weeks was higher than the minimum thresh-
old of 15% specified in the study proposal, the survey
was closed on 22 June 2012. The results were sum-
marized as a percentage for each answer rounded to one
decimal place. The results discussed in this manuscript
are based on this voluntary survey and did not involve
any experimental research on human subjects. Hence,
ethical approval and informed consent procedures were
not applicable.
Results
The survey was sent to 1,273 investigators and researchers,
415 of whom provided feedback, giving a response rate of
32.6%. The respondents were from Europe (38.8%), Asia/
Oceania (20.5%), North America (16.1%), Latin America
(15.2%), Africa (8.0%) and the Middle East (1.5%).
Most respondents (n = 313) were clinical researchers
(Figure 1). Since 2007, 54.7% (n = 227) had published
10 or fewer articles and 83.6% (n = 347) had published
four or fewer articles in collaboration with GSK Vaccines
(Figure 1).
GSK Vaccines’ publications practices
Authorship questionnaire
Since 2011, GSK Vaccines has employed an authorship
questionnaire (see Additional file 1) [25]. Of 273 respon-
dents who had previously completed an authorship
Main research area:
Number of articles published in the last 5 years:



























Figure 1 Profile of participants: main research area and number of articles published in the last five years. Percentages might not add
up to 100% because of rounding.
Camby et al. Trials 2014, 15:446 Page 4 of 12
http://www.trialsjournal.com/content/15/1/446questionnaire, most agreed that its format and content is
appropriate to assess eligibility for authorship according to
ICMJE criteria, that it is a helpful tool for collecting infor-
mation on authors’ contributions and guiding discussions
on authorship, and that the timing of issuing the question-
naire (at the end of the active phase of the study, before
study results are available) was appropriate (Figure 2). Over
two-thirds of respondents agreed that the company
communicates the outcome of the authorship process with
authors appropriately (Figure 2).
Publication briefing meetings and publication outline
At the start of publication writing, all potential authors
(based on results from the authorship questionnaire) areinvited to participate in a briefing meeting to agree
content, journal selection and timelines, and to confirm
authorship and lead authorship. Less than half of respon-
dents (41.2%; n = 171) had taken part in a briefing meet-
ing. Of those who had taken part, over three-quarters
(77.8%; n = 133) agreed that this had provided the oppor-
tunity for taking a greater role in authorship, content and
journal selection, with 4.7% (n = 8) in disagreement and the
remainder (17.5%; n = 30) neither agreeing nor disagreeing.
After the briefing meeting, an outline of the publica-
tion is produced by either the lead author alone or with
writing support from a professional medical writer,
according to the lead author’s preference. The outline is
used as a basis for discussions among authors of the
Figure 2 Experience of the GSK Vaccines authorship questionnaire (based on ICMJE criteria). Answers to the question ‘How much do you
agree/disagree with the following statements?’ (n = 273).
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n = 395) agreed that this step improves the quality of the
first draft of a publication, with 1.2% (n = 5) disagreeing
and 3.6% (n = 15) neither agreeing nor disagreeing.
Publication steering committees and core writing teams
For certain trials, such as an international multicenter
study or a complex study with multiple end-points, a
PSC of external and internal study researchers may be
formed to oversee and produce articles and presenta-
tions from the trial, as outlined in the GPP2 guidelines
[1]. Of the 74 respondents who had been a member of a
PSC, 83.8% (n = 62) agreed that this had provided the
opportunity for a greater role in the publications plan-
ning of larger or complex studies, with 5.4% (n = 4) in
disagreement and the remainder (10.8%, n = 8) neither
agreeing nor disagreeing. Two-thirds of respondents felt
that appointments to a PSC are made in a transparent
manner (66.2% (n = 49); 8.1% (n = 6) disagreed, 25.7%
(n = 19) neither agreed nor disagreed) and that the ra-
tionale for a PSC decision on publication planning and/
or proposal and authorship is well disclosed and justified
(66.2% (n = 49); 8.1% (n = 6) disagreed, 25.7% (n = 19)
neither agreed nor disagreed).A core writing team composed of a small group of
authors may also be formed to lead the development of
manuscript content, although all authors must review
and provide input to the paper. Of the 163 participants
who had been part of a core writing team, nearly all
(96.3%; n = 157) agreed that this was helpful for devel-
oping publications, with 0.6% (n = 1) disagreeing and
3.1% (n = 5) neither agreeing nor disagreeing.
Use of a web-based publication tracking tool
A publication tracking tool (Datavision), designed to
improve efficiency and ensure traceability of each step of
publication development, is used as an interface between
the publication coordinator and authors. Respondents
stated that the key advantages of this tool were access
to an ‘overview of publication status and pending tasks’
(31.0%; 213 of 688 advantages selected; respondents could
select more than one), provision of a ‘secure environment’
(26.0%; n = 179), its ease of use (24.7%; n = 170) and
transparency among users (15.7%; n = 108). Nearly three-
quarters (72.3%; n = 300) of 415 respondents were
satisfied or very satisfied with the use of this tool (8.7%
(n = 36) not satisfied, 19.0% (n = 79) somewhat satisfied),
although not all were familiar with each function, with
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Transparency and communication
The survey included questions that aimed to gain feed-
back on the initiatives introduced since the previous
2009 survey in relation to transparency and communica-
tion of publication development practices. A total of 170
participants had collaborated with GSK Vaccines on
publications before 2009 (41.1% of 414 respondents).
Most (81.4%; 118 of 145) felt that overall transparency had
improved over recent years. Of 101 respondents who had
been involved in PSCs, 81.2% (n = 82) agreed that the
transparency of PSC procedures had improved.Figure 3 Transparency of GSK Vaccines’ publication practices and dec
agree/disagree with the following statements?’ (n =415). aDisclosure of
acknowledgement. bSuch as ICMJE, GPP2, CONSORT, STROBE, PRISMA, C
because of rounding.Most respondents felt that publication development
practices adequately follow international good practice
and reporting guidelines for publications and that com-
munication was clear, proactive and streamlined (Figure 3).
Over three-quarters of respondents agreed that, as au-
thors, they had sufficient access to data to contribute
meaningfully to the publication (Figure 3).
The majority of respondents agreed that they were
kept well informed about publication development,
including target journal requirements (Figure 3), submis-
sion and post-submission status (74.9% (n = 311) agreed,
6.5% (n = 27) disagreed) and publication development
steps, timelines and target journal and congress selec-
tion (71.6% (n = 297) agreed, 9.6% (n = 40) disagreed).ision-making. Answers to the question ‘How much do you
medical writing support, conflicts of interest, contributorship and
HEERS and so on. Percentages might not add up to 100%
Figure 4 ICMJE authorship criteria. Answers to the question
‘How would you rate the clarity of the ICMJE criteria to evaluate
authorship?’ (n = 415). Percentages might not add up to 100%
because of rounding.
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well informed on upcoming publications (11.3% (n = 47)
disagreed) and 58.3% (n = 242) on changes in authorship
(12.5% (n = 52) disagreed). If an individual’s comment on
a manuscript was not taken into account, 65.1% (n = 270)
agreed that they were provided with a clear explanation as
to why this was the case (6.3% (n = 26) disagreed). For
each of these questions, the remainder of respondents
replied ‘neither agree nor disagree’.
General publication practices and standards
International Committee of Medical Journal Editors
authorship criteria
The ICMJE authorship criteria are followed by GSK.
Those in place at the time of the survey were those intro-
duced in 2008 [26] rather than the 2013 revision [16]. The
2008 ICMJE recommendations stated that authorship
should be based on: 1) substantial contributions to con-
ception and design, acquisition of data or analysis and
interpretation of data; 2) drafting the article or revising
it critically for important intellectual content; and 3) final
approval of the version to be published. The ICMJE
authorship criteria were regarded as ‘clear’ or ‘very clear’
to most participants, but 7.7% stated that the criteria were
‘not clear’ or ‘not clear at all’ (Figure 4).
Group authorship
Group authorship is sometimes used in order to attri-
bute authorship (for example, of a multicenter trial) to a
group name. Approximately three-quarters of respon-
dents (75.9%; n = 315) stated that the concept of ‘group
authorship’ is clear to them and 84.6% (341 of 403
respondents) indicated that they would feel comfortable
being part of a group authorship. Those who were not
comfortable with group authorship were invited in an
open question to provide their reasoning; of the 54 com-
ments received, 40.7% (n = 22) explained that group author-
ship had limited academic value, 22.2% (n = 12) felt that
it is only appropriate for certain study designs, 18.5%
(n = 10) stated that its concept is not clear and 18.5%
(n = 10) cited practical issues.
Author agreements and timing of initial manuscript
discussions
The GPP2 guidelines recommend that companies describe
obligations for good publication practice in written publi-
cation agreements with authors and with members of writ-
ing groups or PSCs before the authors begin work [1]. This
concept was popular with respondents; 81.7% (n = 339)
stated that they would be in favor of introducing an ‘author
agreement’ , whereby authors and sponsors formally
agree their respective responsibilities before work starts
on publications.Opinions were divided on the best time to start dis-
cussing a manuscript to be published in a peer-reviewed
journal. The largest percentage (45.8%; n = 190) felt that
discussions should begin at the start of protocol devel-
opment or at the first investigators’ meeting for that
study, while 26.5% (n = 110) felt they should start when
the study’s statistical analysis report can be shared with
investigators and researchers. The remaining respon-
dents felt the appropriate timing was while the study is
ongoing (13.0%; n = 54) or once the study results have
been shared fully with investigators and researchers
(14.7%; n = 61).
Professional medical writers and industry authorship
Professional medical writers work with authors to pre-
pare publications and, in line with ICMJE authorship cri-
teria [16], must be either named as authors or included
in the acknowledgements section of manuscripts [23].
Most respondents agreed that the use of professional
medical writing support can improve the publication
under development, but that having an employee from a
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of acceptance of a manuscript by journal editors (Figure 5).
Just over half of respondents felt that the results of
industry-sponsored research remain under-disclosed in
peer-reviewed publications because of selective reporting
practices (Figure 5).
Discussion
Many pharmaceutical companies have developed policies
for the public disclosure of clinical research data to improve
the transparency and credibility of industry-sponsored
publications [10,13,21-24]. GSK has adopted publication
practices based on international standards, and this survey
gathered respondents’ opinions on the effectiveness of ini-
tiatives introduced following the first assessment in 2009.
Other aims were to identify any remaining gaps in good
publication practices and to gain insight into the under-
standing of publication standards by external authors.
The target population for this survey was investigators
and researchers from different parts of the world who had
previously authored publications in collaboration with
GSK Vaccines. Therefore, respondents were likely to have
been aware of best practices in publication and authorship
criteria. This is a limitation of this study, as the resultsFigure 5 Professional medical writers and industry authorship. Answe
following statements?’ (n = 415). Percentages might not add up to 100% bmay not be representative of the perceptions of investiga-
tors and researchers who have not been involved with
industry-sponsored research publications, or of the views
of internal GSK Vaccines authors who did not take part in
the surveys. The response rate for the survey was 32.6%,
which might have led to response bias but is in line with
average response rates for online surveys [27-29], and
higher than that previously reported in an online survey of
doctors in clinical practice [30].
Overall, the initiatives introduced since the 2009 survey
appear to have been successful in improving transparency
and communication relating to GSK publication develop-
ment practices, as most respondents who had worked
with GSK Vaccines before 2009 stated that overall trans-
parency had improved, as had the transparency of PSC
processes. However, there was some evidence that com-
munication could be improved during publication devel-
opment, particularly with regard to future publications,
changes in authorship and reasons for not including au-
thors’ suggested changes to content. More than 80% of
participants felt that GSK publication practices adequately
follow international good publication practice guidelines
and that communication was clear and proactive. How-
ever, transparency could be improved further as about oners to the question ‘How much do you agree/disagree with the
ecause of rounding.
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access to data to meaningfully contribute to a publication.
Authorship implies responsibility and accountability for
published work [16], and recommendations and guidelines
highlight the importance of ensuring that authors have
access to the full dataset from the study, ideally before
publication writing begins [1,13]. Currently, GSK provides
authors with statistical reports, followed by the full study
report once available, and raw study data are provided
upon request. In response to developments in the GPP
field, the company is in the process of introducing new
procedures, whereby authors will be asked to certify at the
completion of a manuscript that they had the opportunity
to access the analyzed data described in the publication
and that the manuscript’s content is fair, accurate and
balanced. An auditable procedure will be put in place
to ensure that the full study report is shared before
publications are started. GSK has also made commitments
regarding public sharing of its research data [23], includ-
ing the public disclosure of result summaries within
specified periods of time from study completion, pub-
lic availability of full study reports through a clinical trials
register and access to anonymized patient-level data upon
request [31].
In the present survey, 78% of respondents stated that
the ICMJE criteria for authorship are clear to them. This
high level of understanding is likely to have been due to
the fact that all respondents had been involved with the
company’s publication practices, and thus had been ex-
posed to the measures put in place to clarify guidelines.
Similar measures are not always in place, not only for
industry-sponsored publications, but also for publicly-
funded or academic reports [10,12]. In a survey of 295
healthcare professionals, fewer than 60% were aware of
ICMJE authorship criteria [32], and in a smaller survey
of non-industry authors, approximately 40% of respon-
dents were unaware of the ICMJE guidelines [33]. How-
ever, in our survey, one in five respondents did not agree
that the ICMJE authorship criteria were clear. This sug-
gests that not only should the means of communicating
this information be examined, but that the clarity of the
ICMJE authorship criteria to potential authors should be
investigated further. The results of a recent survey con-
ducted in Norway suggest this is particularly important for
less experienced researchers [34]. For example, the term
‘substantial contributions’ included in the first ICMJE cri-
terion can have different meanings to different individuals,
as can the concept of accountability now included in the
fourth criterion of the 2013 recommendations [16]. The
guidelines also suggest that all individuals who meet
the first criterion should have the opportunity to partici-
pate in the review, drafting and final approval of the
manuscript. This could be extremely difficult to achieve
in a reasonable timeframe for trials that involve a verylarge number of study investigators. Issues associated with
authorship have been highlighted by the Medical Publishing
Insights and Practices initiative, which has developed sup-
plemental guidance to help authors set common rules for
authorship early in a trial [35].
The latest ICMJE guidelines also acknowledge that, in-
creasingly, authorship of multicenter trials is attributed
to a group, and state that all members of the group who
are named as authors should fully meet the ICMJE criteria
for authorship [16]. In the 2012 survey, around one-quarter
of respondents stated that the concept of group authorship
is not clear. The updated guidance on group authorship
and contributorship issued by the ICMJE should help im-
prove the perception and understanding of this concept in
industry-sponsored research, although not all journals
adhere to these recommendations. Also, most journals do
not provide practical advice on group authorship in their
instructions for authors [36].
The 2009 survey revealed a lack of clarity about the ra-
tionale for authorship decisions. To address this, and to
be consistent with best practice guidelines, the company
developed an authorship questionnaire and systematic-
ally sends it out to investigators who were involved in a
study and potentially qualify for authorship according to
the first ICMJE authorship criterion [25]. Feedback from
the current survey was encouraging, as most respondents
considered the questionnaire to be a useful tool and judged
its content to be appropriate for its purpose. This sug-
gests that other companies should consider adopting
a similar procedure. However, fewer than 70% of re-
spondents agreed that the outcomes of the authorship
questionnaires were shared sufficiently, and fewer than
60% felt well informed on changes in authorship (around
30% had a neutral opinion), indicating that communica-
tion on authorship determination and alterations can be
improved.
Over 60% of respondents considered that the inclusion
of an industry scientist (who fully meets ICMJE author-
ship criteria) as lead author reduces the likelihood of
acceptance for publication by a journal. There is a lack
of harmonized best practice guidance when it comes to
authorship order and this survey result suggests that nega-
tive perceptions of industry-sponsored research could influ-
ence authorship practices. This is consistent with concerns
raised by the editors and readers of medical journals in rela-
tion to industry-sponsored studies [37-42]. Also, results
from the survey of 295 healthcare professionals revealed
two-thirds of respondents were concerned about pharma-
ceutical employee involvement in manuscript preparation
as authors or reviewers, even if disclosed [43].
Respondents were largely in favor of introducing a for-
malized ‘author agreement’ on responsibilities before start-
ing work on a publication. This has since been adopted by
GSK Vaccines, bringing the company’s policies further in
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opinion on the best time to start discussing a manuscript
also emphasized an early start, at protocol development or
at the first study investigators’ meeting, which usually
takes place after the protocol is finalized and the study has
been approved, but before subject recruitment begins.
Paradoxically, despite this expressed opinion, this has
been difficult to achieve in the past, with the majority of
potential authors preferring to start manuscript discus-
sions when results become available, suggesting a change
in mindset is needed to encourage discussions in the early
stage of trials.
For the development of publication content, like other
pharmaceutical companies, GSK Vaccines employs stan-
dardized procedures and tools for each step, including
briefing meetings, publication outlines, PSCs and core
writing teams, supported by access to a web-based file-
sharing tool. Briefing meetings provide an opportunity
for face-to-face or teleconference discussions, not only
about the content of the manuscript, but to engage
authors in the decision-making process on other aspects
including authorship order, target journal and submis-
sion timelines. Of those who had taken part in a briefing
meeting, more than three-quarters felt this to be of added
value for their role in the publication development. The
publication outline, produced as an outcome of the brief-
ing meeting, was viewed by nearly all respondents as a
valid step which improves the quality of the first draft of
the manuscript.
A PSC may be formed at an early stage to oversee
publications from a trial, as described in the GPP2
guidelines [1]. Others have reported that PSCs enhance
publication development in terms of better involvement
of external authors [44]. In our survey, participation in a
PSC was considered to be helpful in providing the
opportunity for taking a greater role in the planning of
publications. However, improved transparency on PSC
membership and the decision-making processes is needed,
as only two-thirds of respondents felt that the appoint-
ment process to join a PSC is transparent and that the
rationale of PSC decisions is well disclosed and justified.
Nearly all respondents agreed that implementation of a
core writing team, involving a small group of authors, is
beneficial for manuscript development.
The web-based file-sharing tool allows users to manage
the secure circulation and review of each publication draft,
and also allows the publication coordinator to check that
authors have contributed to all stages and provided final
approval. This tool was perceived as advantageous and
most respondents were satisfied with its use. The func-
tionality of this tool continues to evolve to address user
requirements, such as the need to access co-authors’ com-
ments, which was highlighted by the results of the 2009
survey. However, as over a quarter of respondents to the2012 survey did not know how to access this specific
function, it is clearly important to ensure that users know
how to use this tool.
In the present survey, nearly 90% of respondents agreed
that the use of professional medical writing support can
add value in the development of a manuscript. This was in
broad agreement with other surveys that have examined
perceptions of professional medical writers. In a survey of
204 healthcare professionals with previous publications,
68% said they would agree to be an author of a publication
developed with medical writing assistance [43]. Further, a
survey of 76 authors reported that 83% felt it was accept-
able to receive assistance and 84% valued the assistance
provided by professional medical writers [45]. However, of
295 healthcare professionals, 30% stated that they would
trust a peer-reviewed publication less if medical writers
were involved and only 14% would trust it more [43],
which is consistent with reports of concern in the medical
literature about the involvement of professional medical
writers [9,46,47]. This may be partly due to the frequent
description of professional medical writing assistance as
ghostwriting [48]. Professional medical writers work with
authors to prepare publications while ensuring authors
control and direct writing, and that disclosures of funding,
potential conflicts of interest and acknowledgment of con-
tributions are made [1,49]. In contrast, ghostwriters are
individuals who analyze data and/or write manuscripts,
but are not acknowledged in the publication [9,10,47].
In line with other pharmaceutical companies [10,21,24],
GSK’s policy is to name professional medical writers in
the article either as authors when their contribution meets
authorship criteria, or by description of their contribution
within the acknowledgements section [23]. However, the
level of concern surrounding professional medical writer
involvement, and industry-sponsored research in general,
suggests that further efforts are needed to highlight the
distinction between writing and editing contributorship
and authorship. This may include standardization of the
definition of ghostwriting, as well as an open debate of the
ethics and value of professional medical writing assistance
[10,13,48,50].
Conclusions
The pharmaceutical industry has acted to counter criticisms
of publication practices for industry-sponsored research by
incorporating internationally-recognized recommendations
and guidelines into their policies and standard practices,
but opportunities remain for additional improvement [13].
Prompted by the results of a clinical investigator survey
conducted in 2009, GSK Vaccines made changes to its
publication practices to improve transparency and com-
munication with external authors. The results of this sec-
ond survey conducted in 2012 suggest that these changes
have been effective to a large extent, but that further
Camby et al. Trials 2014, 15:446 Page 11 of 12
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tion practices.
Overall, the usefulness and suitability of the company’s
publication practices were acknowledged by the majority
of external authors responding to this survey. Authors
were in favor of initiating discussions about publications,
including authorship, at an early stage and with the intro-
duction of a formal ‘author agreement’ from the outset.
There was some evidence that external authors would
benefit from improved transparency and communication
from GSK Vaccines in relation to the outcomes of the
authorship questionnaire, changes in authorship, publica-
tion progress and future publications. Although PSCs are
recognized to be valuable, there was sometimes a lack of
clarity in PSC procedures and outcomes. The need for im-
proved communication in relation to outcomes of author-
ship selection and on the practical use of the web-based
publication tracking tool was also highlighted, as well
as the need for sufficient access to relevant data for
all authors. The company’s publication practices are be-
ing strengthened to ensure data access that permits mean-
ingful contributions by all authors to each publication.
Moreover, the results suggest further clarification of best
practices for authorship should be provided in inter-
national recommendations and in journals’ instructions
to authors.
The survey results confirm the need for publication
practices and tools that ensure effective and timely com-
munication, and transparent processes for authorship
and decision-making. The identified gaps in good publi-
cation practice will help to guide further improvements
to the company’s policies on publication development.
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